Hostname: page-component-7c8c6479df-ph5wq Total loading time: 0 Render date: 2024-03-29T02:33:41.833Z Has data issue: false hasContentIssue false

Current status and clinical association of beta-catenin with juvenile nasopharyngeal angiofibroma

Published online by Cambridge University Press:  30 August 2016

A Mishra*
Affiliation:
Department of Otorhinolaryngology, King George Medical University, Lucknow, India
V Singh
Affiliation:
Department of Otorhinolaryngology, King George Medical University, Lucknow, India
V Verma
Affiliation:
Department of Otorhinolaryngology, King George Medical University, Lucknow, India
S Pandey
Affiliation:
Department of Biochemistry, King George Medical University, Lucknow, India
R Trivedi
Affiliation:
Department of Endocrinology, Central Drug Research Institute, Lucknow, India
H P Singh
Affiliation:
Department of Otorhinolaryngology, King George Medical University, Lucknow, India
S Kumar
Affiliation:
Department of Otorhinolaryngology, King George Medical University, Lucknow, India
R C Dwivedi
Affiliation:
Department of Otolaryngology and Head and Neck Surgery, Queen Alexandra Hospital, Portsmouth Hospitals NHS Trust, UK
S C Mishra
Affiliation:
Department of Otorhinolaryngology, Nepalgunj Medical College, Kohlpur, Nepal
*
Address for correspondence: Dr Anupam Mishra, Department of Otorhinolaryngology, King George Medical University, Lucknow, India E-mail: amishra_ent@yahoo.com

Abstract

Objective:

A possible role of the APC/beta-catenin pathway in the pathogenesis of sporadic juvenile nasopharyngeal angiofibroma has been suggested. This paper presents its current status and clinical association in our patients.

Method:

A prospective observational study was conducted at King George Medical University and Central Drug Research Institute, in Lucknow, India. Western blot analysis was undertaken in 16 cases to examine beta-catenin expression. The clinical details were recorded along with follow up observations, to determine associations.

Results:

Up-regulation of beta-catenin expression was seen in 69 per cent of cases. The clinical variables did not reveal significant differences between patients with extremes of expression (extreme under- vs over-expression). However, absent expression was shown exclusively in young adults aged over 18 years, while enhanced expression was associated with an altered facial profile.

Conclusion:

Although a beta-catenin association was seen in a subset of our sporadic juvenile nasopharyngeal angiofibroma cases, its expression was not homogeneous. This is in contrast to the Western literature that suggests a universal (homogenous) enhanced expression in the majority. Hence, further research is required to better define its molecular cascade.

Type
Main Articles
Copyright
Copyright © JLO (1984) Limited 2016 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1 Barth, AI, Nathke, IS, Nelson, WJ. Cadherins, catenins and APC protein: interplay between cytoskeletal complexes and signaling pathways. Curr Opin Cell Biol 1997;9:683–90CrossRefGoogle ScholarPubMed
2 Behrens, J, von Kries, JP, Kühl, M, Bruhn, L, Wedlich, D, Grosschedl, R et al. Functional interaction of beta-catenin with the transcription factor LEF-1. Nature 1996;382:638–42Google Scholar
3 Rubinfeld, B, Albert, I, Porfiri, E, Fiol, C, Munemitsu, S, Polakis, P. Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex assembly. Science 1996;272:1023–6Google Scholar
4 Munemitsu, S, Albert, I, Souza, B, Rubinfeld, B, Polakis, P. Regulation of intracellular beta-catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein. Proc Natl Acad Sci U S A 1995;92:3046–50Google Scholar
5 Aberle, H, Bauer, A, Stappert, J, Kispert, A, Kemler, R. Beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J 1997;16:3797–804Google Scholar
6 Orford, K, Crockett, C, Jensen, JP, Weissman, AM, Byers, SW. Serine phosphorylation-regulated ubiquitination and degradation of beta-catenin. J Biol Chem 1997;272:24735–8Google Scholar
7 Morin, PJ, Sparks, AB, Korinek, V, Barker, N, Clevers, H, Vogelstein, B et al. Activation of beta-catenin-Tcf signaling in colon cancers by mutations in beta-catenin or APC. Science 1997;275:1787–90CrossRefGoogle ScholarPubMed
8 Korinek, V, Barker, N, Morin, PJ, van Wichen, D, de Weger, R, Kinzler, KW et al. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon cancer. Science 1997;275:1784–7Google Scholar
9 Kinzler, KW, Vogelstein, B. Lessons from hereditary colorectal cancer. Cell 1996;87:159–70Google Scholar
10 Sparks, AB, Morin, PJ, Vogelstein, B, Kinzler, KW. Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. Cancer Res 1998;58:1130–4Google Scholar
11 Gardner, EJ. Follow-up study of a family group exhibiting dominant inheritance for a syndrome including intestinal polyps, osteomas, fibromas, and epidermal cysts. Am J Hum Genet 1962;14:376–90Google Scholar
12 Klemmer, S, Pascoe, L, DeCosse, J. Occurrence of desmoids in patients with familial adenomatous polyposis of the colon. Am J Med Genet 1987;28:385–92Google Scholar
13 Krush, AJ, Traboulsi, EI, Offerhaus, GJ, Maumenee, IH, Yardley, JH, Levin, LS. Hepatoblastoma, pigmented ocular fundus lesions and jaw lesions in Gardner syndrome. Am J Med Genet 1988;29:323–32Google Scholar
14 Bell, B, Mazzaferri, EL. Familial adenomatous polyposis (Gardner's syndrome) and thyroid carcinoma: a case report and review of the literature. Dig Dis Sci 1993;38:185–90CrossRefGoogle ScholarPubMed
15 Walsh, N, Qizilbash, A, Banerjee, R, Waugh, GA. Biliary neoplasia in Gardner's syndrome. Arch Pathol Lab Med 1987;111:76–7Google ScholarPubMed
16 Hamilton, SR, Liu, B, Parsons, RE, Papadopoulos, N, Jen, J, Powell, SM et al. The molecular basis of Turcot's syndrome. N Engl J Med 1995;332:839–47Google Scholar
17 Giardiello, FM, Hamilton, SR, Krush, AJ, Offerhaus, JA, Booker, SV, Petersen, GM. Nasopharyngeal angiofibroma in patients with familial adenomatous polyposis. Gastroenterology 1993;105:1550–2Google Scholar
18 Ferouz, AS, Morh, RM, Paul, P. Juvenile nasopharyngeal angiofibroma and familial adenomatous polyposis: an association? Otolaryngol Head Neck Surg 1995;113:435–9.Google Scholar
19 Abraham, SC, Montgomery, EA, Giardiello, FM, Wu, TT. Frequent beta-catenin mutations in juvenile nasopharyngeal angiofibromas. Am J Pathol 2001;158:1073–8Google Scholar
20 Klockars, T, Renkonen, S, Leivo, I, Hagström, J, Mäkitie, AA. Juvenile nasopharyngeal angiofibroma: no evidence for inheritance or association with familial adenomatous polyposis. Fam Cancer 2010;9:401–3Google Scholar
21 Lerner, C, Wemmert, S, Schick, B. Preliminary analysis of different microRNA expression levels in juvenile angiofibromas. Biomed Rep 2014;2:835–8Google Scholar
22 Mishra, A, Mishra, SC. Changing trends in the incidence of juvenile nasopharyngeal angiofibroma: seven decades of experience at King George's Medical University, Lucknow, India. J Laryngol Otol 2016;130:363–8CrossRefGoogle Scholar
23 Mishra, SC, Shukla, GK, Bhatia, N, Pant, MC. A rational classification of angiofibromas of the postnasal space. J Laryngol Otol 1989;103:912–16Google Scholar
24 Pawlowski, JE, Ertel, JR, Allen, MP, Xu, M, Butler, C, Wilson, EM et al. Liganded androgen receptor interaction with beta-catenin: nuclear co-localization and modulation of transcriptional activity in neuronal cells. J Biol Chem 2002;277:20702–10CrossRefGoogle ScholarPubMed
25 Valanzano, R, Curia, MC, Aceto, G, Veschi, S, De Lellis, L, Catalano, T et al. Genetic evidence that juvenile nasopharyngeal angiofibroma is an integral FAP tumour. Gut 2005;54:1046–7Google Scholar
26 Guertl, B, Beham, A, Zechner, R, Stammberger, H, Hoefler, G. Nasopharyngeal angiofibroma: an APC-gene associated tumor? Hum Pathol 2000;31:1411–13Google Scholar
27 Garcia-Rostan, G, Tallini, G, Herrero, A, D'Aquila, TG, Carcangiu, ML, Rimm, DL. Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma. Cancer Res 1999;59:1811–15Google Scholar
28 Voeller, HJ, Truica, C, Gelmann, EP. Beta-catenin mutations in human prostate cancer. Cancer Res 1998;58:2520–3Google Scholar
29 Fukuchi, T, Sakamoto, M, Tsuda, H, Maruyama, K, Nozawa, S, Hirohashi, S. Beta-catenin mutation in carcinoma of the uterine endometrium. Cancer Res 1998;58:3526–8Google Scholar
30 Palacios, J, Gamallo, C. Mutations in the beta-catenin gene (CTNNB1) in endometrioid ovarian carcinomas. Cancer Res 1998;58:1344–7Google ScholarPubMed
31 Mirabelli-Primdahl, L, Gryfe, R, Kim, H, Millar, A, Luceri, C, Dale, D et al. Beta-catenin mutations are specific for colorectal carcinomas with microsatellite instability but occur in endometrial carcinomas irrespective of mutator pathway. Cancer Res 1999;59:3346–51Google Scholar
32 Koesters, R, Ridder, R, Kopp-Schneider, A, Betts, D, Adams, V, Niggli, F et al. Mutational activation of the beta-catenin proto-oncogene is a common event in the development of Wilms’ tumors. Cancer Res 1999;59:3880–2Google Scholar
33 Miyoshi, Y, Iwao, K, Nagasawa, Y, Aihara, T, Sasaki, Y, Imaoka, S et al. Activation of the beta-catenin gene in primary hepatocellular carcinomas by somatic alterations involving exon 3. Cancer Res 1998;58:2424–7Google Scholar
34 Huang, H, Fujii, H, Sankila, A, Mahler-Araujo, BM, Matsuda, M, Cathomas, G et al. Beta-catenin mutations are frequent in human hepatocellular carcinomas associated with hepatitis C virus infection. Am J Pathol 1999;155:1795–801Google Scholar
35 Hus, HC, Jeng, YM, Mao, TL, Chu, JS, Lai, PL, Peng, SY. Beta-catenin mutations are associated with a subset of low-grade hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis. Am J Pathol 2000;157:763–70Google Scholar
36 Zhang, PJ, Weber, R, Liang, H, Pasha, TL, LiVolsi, VA. Growth factors and receptors in juvenile nasopharyngeal angiofibroma and nasal polyps. Arch Pathol Lab Med 2003;127:1480–4Google Scholar